https://www.frontiersin.org/research-topics/33411/idiopathic-pulmonary-fibrosis-epidemiology-prognosis-and-treatment/magazine
Idiopathic pulmonary fibrosis is a chronic progressive disease with unknown etiology. The prognosis of idiopathic pulmonary fibrosis is very poor, indeed if...
idiopathic pulmonary fibrosisepidemiologyprognosistreatmentfrontiers
https://www.openpr.com/news/4293196/idiopathic-pulmonary-fibrosis-ipf-clinical-market-to-reach
Press release - Exactitude Consultancy - Idiopathic Pulmonary Fibrosis (IPF) Clinical Market to Reach USD 6.2 Billion by 2030 - published on openPR.com
idiopathic pulmonary fibrosisipfclinicalmarketreach
https://scirp.org/journal/papercitationdetails?paperid=35767&journalid=30
Idiopathic pulmonary fibrosis (IPF) is characterized by exuberant apoptosis and inadequate regeneration of lung parenchyma cells. Intratracheal alveolar type...
stem cell therapyidiopathic pulmonary fibrosishow far
https://pubmed.ncbi.nlm.nih.gov/35930918/
Nearly one third of patients with IPF were diagnosed incidentally, and their survival was still poor. Identifying patients during the earliest stage of IPF,...
outcomepatientsincidentallydiagnosedidiopathic
https://www.prnewswire.com/news-releases/prometics-pbi-4050-demonstrates-early-evidence-of-efficacy-in-its-idiopathic-pulmonary-fibrosis-ipf-phase-2-clinical-trial-601656265.html
/PRNewswire/ -- ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("ProMetic" or the "Corporation") announced today positive interim results from its...
pbidemonstratesearlyevidenceefficacy